866-997-4948(US-Canada Toll Free)

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

Published By :

GBI Research

Published Date : Jan 2011

Category :

Diseases & Conditions

No. of Pages : 296 Pages


GBI Research has released its latest research Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets, which essentially provides insights into diabetes therapeutics sales and price forecasts until 2016. The report also examines the global diabetes therapies treatment usage patterns. 

The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2016 are included. The report provides an in-depth analysis of HIV, Hepatitis, Herpes and Influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these two therapeutic indications. 

The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

According to the study done by GBI Research, the HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% between 2008 and 2015. 

Scope

  • Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the diabetes therapeutics market from 2001 to 2009, with forecasts to 2016.
  • Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market.
  • Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi-Aventis, Takeda Pharmaceuticals, Merck, GlaxoSmithKline, Roche, Bristol Myers Squibb and Gilead.

Reasons to buy

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Global Antivirals Market: Introduction
2.1 GBI Research Report Guidance

3 Global HIV Therapeutics Market: Overview
3.1 Disease Overview
3.2 Market Overview

4 Global HIV Therapeutics Market: Market Characterization
4.1 Market Forecasts
4.2 Annual Cost of Therapy
4.3 Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.3.5 Usage Patterns
4.3.6 Geographical Distribution
4.4 HIV Therapeutics Market: Drivers and Restraints
4.5 Market Drivers
4.5.1 Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population
4.5.2 New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake
4.5.3 Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics
4.6 Market Restraints
4.6.1 Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions
4.6.2 Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base
4.6.3 Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes

5 Global HIV Therapeutics Market: The US Market
5.1 Market Forecasts
5.2 Annual Cost of Therapy
5.3 Usage Patterns
5.3.1 Diseased Population
5.3.2 Treatment Seeking Population
5.3.3 Diagnosis Population
5.3.4 Prescription Population
5.3.5 Usage Patterns

6 Global HIV Therapeutics Market: Europe Market

6.1 Market Forecasts
6.2 Annual Cost of Therapy
6.3 Usage Patterns
6.3.1 Diseased Population
6.3.2 Treatment Seeking Population
6.3.3 Diagnosis Population
6.3.4 Prescription Population
6.3.5 Usage Patterns

7 Global HIV Therapeutics Market: Japan Market

7.1 Market Forecasts
7.2 Annual Cost of Therapy
7.3 Usage Patterns
7.3.1 Diseased Population
7.3.2 Treatment Seeking Population
7.3.3 Diagnosis Population
7.3.4 Prescription Population
7.3.5 Usage Patterns

8 Global HIV Therapeutics Market: Major Drug Classes

8.1 Different Classes of Drugs
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
8.1.3 Protease Inhibitors
8.1.4 Viral Fusion (or Entry) Inhibitors
8.1.5 HIV Integrase Strand Transfer Inhibitors
8.1.6 Multi-class Combination Products
8.2 Pipeline Analysis
8.2.1 Phase I
8.2.2 Phase II
8.2.3 Phase III

9 Global Hepatitis Therapeutics Market: Market Overview
9.1 Introduction
9.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market
9.2.1 Sales Value
9.2.2 Annual Cost of Therapy
9.2.3 Treatment Usage Patterns
9.3 Hepatitis Market Drivers
9.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline
9.3.2 Promising Developments in the Hepatitis C Pipeline
9.3.3 Steady Increase in Prescription Population
9.4 Hepatitis Market Restraints
9.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms During the Acute Phase
9.4.2 Low Treatment Seeking Population
9.4.3 Loss of Exclusivity Protection in Hepatitis B Market
9.5 Generic Share in the Global Hepatitis Market

10 Global Hepatitis Market: Therapeutic Landscape

10.1 Introduction
10.1.1 Hepatitis A
10.1.2 Hepatitis B
10.2 Overview of Hepatitis A and B Vaccines Market
10.2.1 Sales Value
10.3 Hepatitis B Market
10.3.1 Introduction
10.3.2 Sales Value
10.3.3 Annual Cost of Therapy
10.3.4 Treatment Usage Patterns
10.3.5 Geographical Segmentation
10.4 Hepatitis C Market
10.4.1 Introduction
10.4.2 Sales Value
10.4.3 Annual Cost of Therapy
10.4.4 Treatment Usage Patterns
10.4.5 Geographical Segmentation

11 Global Hepatitis Market: Geographical Landscape
11.1 Geographical Break-up
11.2 The US
11.2.1 Sales Value
11.2.2 Annual Cost of Therapy
11.2.3 Treatment Usage Patterns
11.3 Top Five Countries in Europe
11.3.1 Sales Value
11.3.2 Annual Cost of Therapy
11.3.3 Treatment Usage Patterns
11.4 Japan
11.4.1 Sales Value
11.4.2 Annual Cost of Therapy
11.4.3 Treatment Usage Patterns
11.5 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis
11.6 Introduction
11.6.1 Research and Development Pipeline - Hepatitis B Therapeutics
11.6.2 Research and Development Pipeline - Hepatitis C Therapeutics

12 Herpes Simplex Therapeutics Market: Market Characterization

12.1 Overview
12.2 Herpes Simplex Therapeutics Market Size
12.3 Herpes Simplex Therapeutics Market Forecast and CAGR
12.4 Drivers and Barriers for the Herpes Simplex Therapeutics Market
12.4.1 Drivers for the Herpes Simplex Therapeutics Market
12.4.2 Barriers for the Herpes Simplex Therapeutics Market
12.5 Herpes Simplex Therapeutics Market: Competitive Assessment
12.6 Overview
12.7 Strategic Competitor Assessment
12.8 Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market
12.8.1 Zovirax (Acyclovir)
12.8.2 Famvir (Famciclovir)
12.8.3 Valtrex (Valacyclovir)

13 Herpes Simplex Therapeutics Market: Pipeline Assessment
13.1 Overview
13.2 Herpes Simplex Therapeutics - Promising Drugs under Clinical Development
13.3 Molecule Profiles for Promising Drugs under Clinical Development
13.3.1 BA-021 (Acyclovir Lauriad)
13.3.2 RPI-78M
13.3.3 AIC316
13.4 Herpes Simplex Therapeutics Market - Pipeline Assessment by Mechanism of Action
13.5 Herpes Simplex Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
13.5.1 Herpes Simplex Therapeutics - Phase III Clinical Pipeline
13.5.2 Herpes Simplex Therapeutics - Phase II Clinical Pipeline
13.5.3 Herpes Simplex Therapeutics - Phase I Clinical Pipeline
13.5.4 Herpes Simplex Therapeutics - Preclinical Pipeline

14 Global Influenza Therapeutics Market: Overview
14.1 Disease Overview
14.2 Influenza
14.3 Market Overview

15 Global Influenza Therapeutics Market: Market Characterization
15.1 Market Forecasts
15.2 Annual Cost of Therapy
15.3 Usage Patterns
15.3.1 Diseased Population
15.3.2 Treatment Seeking Population
15.3.3 Diagnosis Population
15.3.4 Usage Patterns
15.3.5 Geographical Distribution

16 Global Influenza Therapeutics Market: The US Market
16.1 Market Forecasts
16.2 Annual Cost of Therapy
16.3 Usage Patterns
16.3.1 Diseased Population
16.3.2 Treatment Seeking Population
16.3.3 Diagnosis Population
16.3.4 Prescription Population
16.3.5 Usage Patterns

17 Global Influenza Therapeutics Market: Europe Market
17.1 Market Forecasts
17.2 Annual Cost of Therapy
17.3 Usage Patterns

17.3.1 Diseased Population
17.3.2 Treatment Seeking Population
17.3.3 Diagnosis Population
17.3.4 Prescription Population
17.3.5 Usage Patterns

18 Global Influenza Therapeutics Market: Japan Market
18.1 Market Forecasts
18.2 Annual Cost of Therapy
18.3 Usage Patterns
18.3.1 Diseased Population
18.3.2 Treatment Seeking Population
18.3.3 Diagnosis Population
18.3.4 Prescription Population
18.3.5 Usage Patterns

19 Pipeline Analysis
19.1.1 Phase I
19.1.2 Phase II
19.1.3 Phase III- Major Pipeline Products and their Mechanisms of Action

20 Antivirals Market- Competitive Landscape
20.1 Global HIV/AIDs Market: Competitive Landscape
20.2 Major Company Profiles
20.2.1 Gilead
20.2.2 GlaxoSmithKline (GSK)
20.2.3 Bristol-Myers Squibb (BMS)
20.2.4 Abbott Laboratories
20.2.5 Merck
20.2.6 Pfizer
20.3 Global Hepatitis Therapeutics Market- Competive Landcape
20.4 Major Company Profiles
20.4.1 Merck & Co., Inc.
20.4.2 F. Hoffmann-La Roche Ltd.
20.4.3 GlaxoSmithKline plc
20.5 Global Herpes Simplex Market: Competitive Landscape
20.6 Major Company Profiles
20.6.1 BioAlliance Pharma
20.6.2 Nutra Pharma Corporation
20.6.3 AiCuris GmbH and Co. KG

21 Global Antivirals Therapeutics Market: Strategic Consolidations
21.1 Global HIV/AIDS Market
21.1.1 Overview: Deals by Type and Geography
21.1.2 Mergers and Acquisitions
21.1.3 Licensing Agreements
21.2 Global Hepatitis Market
21.2.1 Overview: Deals by Type and Geography
21.2.2 Mergers and Acquisitions
21.2.3 Licensing Agreements
21.3 Global Herpes Market
21.3.1 Mergers and Acquisitions
21.3.2 Licensing Agreements
21.4 Global Influenza Therapeutics Market
21.4.1 Mergers and Acquisitions
21.4.2 Licensing Agreements

22 Antivirals Market: Appendix
22.1 Market Definitions
22.2 Abbreviations
22.3 Research Methodology
22.3.1 Coverage
22.3.2 Secondary Research
22.3.3 Primary Research
22.3.4 Forecasts
22.3.5 Expert Panel Validation
22.4 Contact Us
22.5 Disclaimer
22.6 Sources

List of Table


Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2001-2009 20
Table 2: HIV Market, Global, Revenue ($m), 2009-2016 20
Table 3: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 22
Table 4: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 22
Table 5: HIV Therapeutics Market, Global, Diseased Population(000), 2001-2009 24
Table 6: HIV Therapeutics Market, Global, Diseased Population(000), 2009-2016 24
Table 7: HIV Therapeutics Market, Global, Treatment Seeking Population(000), 2001-2009 25
Table 8: HIV Therapeutics Market, Global, Treatment Seeking Population(000), 2009-2016 25
Table 9: HIV Therapeutics Market, Global, Diagnosis Population, 2001-2009 28
Table 10: HIV Therapeutics Market, Global, Diagnosis Population, 2009-2016 28
Table 11: HIV Therapeutics Market, Global, Prescription Population, 2001-2009 30
Table 12: HIV Therapeutics Market, Global, Prescription Population, 2009-2016 30
Table 13: HIV Therapeutics Market, Global, Usage Patterns(000), 2001-2009 32
Table 14: HIV Therapeutics Market, Global, Usage Patterns(000), 20092016 32
Table 15: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2009-2016 37
Table 16: HIV Therapeutics Market, US, Revenues ($m), 2001-2009 40
Table 17: HIV Therapeutics Market, US, Revenue ($m), 20092016 40
Table 18: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 2001-2009 41
Table 19: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 2009-2016 41
Table 20: HIV Therapeutics Market, US, Diseased Population(000), 2001-2009 43
Table 21: HIV Therapeutics Market, US, Diseased Population(000), 20092016 43
Table 22: HIV Therapeutics Market, US, Treatment Seeking Population(000), 2001-2009 44
Table 23: HIV Therapeutics Market, US, Treatment Seeking Population(000), 2009-2016 44
Table 24: HIV Therapeutics Market, US, Diagnosis Population(000), 2001-2009 46
Table 25: HIV Therapeutics Market, US, Diagnosis Population(000), 2009-2016 46
Table 26: HIV Therapeutics Market, US, Prescription Population(000), 2001-2009 48
Table 27: HIV Therapeutics Market, US, Prescription Population(000), 20092016 48
Table 28: HIV Therapeutics Market, US, Usage Patterns(000), 2001-2009 50
Table 29: HIV Therapeutics Market, US, Usage Patterns(000), 20092016 50
Table 30: HIV Therapeutics Market, Europe, Revenues ($m), 2001-2009 52
Table 31: HIV Therapeutics Market, Europe, Revenue ($m), 20092016 52
Table 32: HIV Therapeutics Market, Europe, Average Cost of Treatment($), 2001-2009 54
Table 33: HIV Therapeutics Market, Europe, Average Cost of Treatment($), 20092016 54
Table 34: HIV Therapeutics Market, Europe, Diseased Population(00), 2001-2009 55
Table 35: HIV Therapeutics Market, Europe, Diseased Population(00), 20092016 55
Table 36: HIV Therapeutics Market, Europe, Treatment Seeking Population(00), 2001-2009 57
Table 37: HIV Therapeutics Market, Europe, Treatment Seeking Population(00), 20092016 57
Table 38: HIV Therapeutics Market, Europe, Diagnosis Population(00), 2001-2009 59
Table 39: HIV Therapeutics Market, Europe, Diagnosis Population(00), 2009-2016 59
Table 40: HIV Therapeutics Market, Europe, Prescription Population(00), 2001-2009 60
Table 41: HIV Therapeutics Market, Europe, Prescription Population(00), 2009-2016 60
Table 42: HIV Therapeutics Market, Europe, Usage Patterns, 2001-2009 62
Table 43: HIV Therapeutics Market, Europe, Usage Patterns, 2009-2016 62
Table 44: HIV Therapeutics Market, Japan, Revenue ($m), 2001-2009 64
Table 45: HIV Therapeutics Market, Japan, Revenue ($m), 2009-2016 64
Table 46: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 65
Table 47: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 65
Table 48: HIV Therapeutics Market, Japan, Diseased Population(00), 2001-2009 66
Table 49: HIV Therapeutics Market, Japan, Diseased Population(00), 2009-2016 66
Table 50: HIV Therapeutics Market, Japan, Treatment Seeking Population(00), 2001-2009 67
Table 51: HIV Therapeutics Market, Japan, Treatment Seeking Population(00), 2009-2016 67
Table 52: HIV Therapeutics Market, Japan, Diagnosis Population(00), 2001-2009 68
Table 53: HIV Therapeutics Market, Japan, Diagnosis Population(00), 2009-2016 68
Table 54: HIV Therapeutics Market, Japan, Prescription Population(00), 2001-2009 69
Table 55: HIV Therapeutics Market, Japan, Prescription Population(00), 2009-2016 69
Table 56: HIV Therapeutics Market, Japan, Usage Patterns(000), 2001-2009 70
Table 57: HIV Therapeutics Market, Japan, Usage Patterns, 2009-2016 71
Table 58: HIV Market, Global, Different Classes of Drugs 73
Table 59: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2009-2010 76
Table 60: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2009-2010 84
Table 61: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2009-2010 97
Table 62: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20012009 106
Table 63: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20092016 106
Table 64: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20012009 107
Table 65: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20092016 107
Table 66: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 20012009 108
Table 67: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 20092016 109
Table 68: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20012009 118
Table 69: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20092016 118
Table 70: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20012009 120
Table 71: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20092016 120
Table 72: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 20012009 121
Table 73: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 20092016 121
Table 74: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (000), 20012009 122
Table 75: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (000), 20092016 123
Table 76: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20012009 128
Table 77: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20092016 128
Table 78: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20012009 130
Table 79: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20092016 130
Table 80: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 20012009 131
Table 81: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 20092016 131
Table 82: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 20012009 132
Table 83: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 20092016 133
Table 84: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 20012009 139
Table 85: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 20092016 139
Table 86: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20012009 142
Table 87: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20092016 142
Table 88: Hepatitis Therapeutics Market, US, Sales Value ($m), 20012009 144
Table 89: Hepatitis Therapeutics Market, US, Sales Value ($m), 20092016 144
Table 90: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20012009 145
Table 91: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20092016 145
Table 92: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (000), 20012009 146
Table 93: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (000), 20092016 147
Table 94: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 20012009 152
Table 95: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 20092016 152
Table 96: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20012009 154
Table 97: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20092016 154
Table 98: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000), 20012009 155
Table 99: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000s), 20092016 156
Table 100: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20012009 160
Table 101: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20092016 160
Table 102: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012009 161
Table 103: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20092016 161
Table 104: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (000), 20012009 162
Table 105: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (000), 20092016 163
Table 106: Hepatitis Therapeutics Market, Global, R&D Pipeline in Hepatitis B, 2010 172
Table 107: Hepatitis Therapeutics Market, Global, R&D Pipeline in Hepatitis C, 2010 177
Table 108: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 192
Table 109: Herpes Simplex Therapeutics Market, Global, Market Forecast ($), 2009-2016 193
Table 110: Major Marketed Products Comparison in Herpes Simplex Market, 2010 200
Table 111: Simplex Therapeutics Market Most Promising Drugs under Clinical Development, 2010 201
Table 112: Herpes Simplex Market Phase III Clinical Pipeline, 2010 204
Table 113: Herpes Simplex Therapeutics Market Phase II Clinical Pipeline, 2010 205
Table 114: Herpes Simplex Market Phase I Clinical Pipeline, 2010 205
Table 115: Herpes Simplex Market Discovery and Preclinical Pipeline, 2010 206
Table 116: Influenza Therapeutics Market Revenue, Global ($bn), 2001-2007e 209
Table 117: Influenza Therapeutics Market Revenue, Global ($bn), 2009-2016 209
Table 118: Influenza Therapeutics Market, Annual Cost of Therapy, Global ($), 2002-2009 210
Table 119: Influenza Therapeutics Market, Annual Cost of Therapy, Global ($), 2009-2016 210
Table 120: Influenza Therapeutics Market, Global, Diseased Population(Million), 20022009 211
Table 121: Influenza Therapeutics Market, Global, Diseased Population(Million), 20092016 211
Table 122: Influenza Therapeutics Market, Global, Treatment Seeking Population(Million), 20022009 212
Table 123:Influenza Therapeutics Market, Global, Treatment Seeking Population(Million), 20092016 212
Table 124: Influenza Therapeutics Market, Global, Diagnosis Population(Million), 20022009 213
Table 125: Influenza Therapeutics Market, Global, Diagnosis Population(Million), 20092016 213
Table 126: Influenza Therapeutics Market, Global, Diseased Population(Million), 20022009 214
Table 127: Influenza Therapeutics Market, Global, Diseased Population, 20092016 214
Table 128: Influenza Therapeutics Market, US, Revenues ($bn), 20012009 216
Table 129: Influenza Therapeutics Market, US, Revenues ($bn), 20092016 216
Table 130: InfluenzaTherapeutics Market, US, Annual Cost of Therapy ($), 20022009 217
Table 131: InfluenzaTherapeutics Market, US, Annual Cost of Therapy ($), 20092016 217
Table 132: Influenza Therapeutics, US, Diseased Population(Million), 2002-2009 218
Table 133: Influenza Therapeutics, US, Diseased Population(Million), 2009-2016 218
Table 134:Influenza Therapeutics Market, US, Treatment Seeking Population(Million), 20022009 219
Table 135:Influenza Therapeutics Market, US, Treatment Seeking Population(Million), 20092016 219
Table 136: Influenza Therapeutics Market, US, Diagnosis Population(Million), 20022009 220
Table 137: Influenza Therapeutics Market, US, Diagnosis Population(Million), 20092016 220
Table 138: Influenza Therapeutics Market, US, Usage Patterns(Million), 20022009 222
Table 139: Influenza Therapeutics Market, US, Usage Patterns(Million), 20092016 222
Table 140: Influenza Therapeutics Market, Europe, Revenues ($bn), 20012009 224
Table 141: Influenza Therapeutics Market, Europe, Revenues ($bn), 20092016 224
Table 142: Influenza Therapeutics Market, Europe, Average Cost of Treatment, 20022009 225
Table 143: Influenza Therapeutics Market, Europe, Average Cost of Treatment, 20092016 225
Table 144: Influenza Therapeutics Market, Europe, Diseased Population(Million), 20022009 226
Table 145: Influenza Therapeutics Market, Europe, Diseased Population(Million), 20092016 226
Table 146: Influenza Therapeutics Market, Europe, Treatment Seeking Population(Million), 20022009 227
Table 147: Influenza Therapeutics Market, Europe, Treatment Seeking Population(Million), 20092016 227
Table 148: Influenza Therapeutics Market, Europe, Diagnosis Population, 20022009 228
Table 149: Influenza Therapeutics Market, Europe, Diagnosis Population, 20092016 228
Table 150: Influenza Therapeutics Market, Europe, Usage Patterns(Million), 20022009 230
Table 151: Influenza Therapeutics Market, Europe, Usage Patterns(Million), 20092016 231
Table 152: Influenza Therapeutics Market, Japan, Revenues ($bn), 20012009 232
Table 153: Influenza Therapeutics Market, Japan, Revenues ($bn), 20092016 232
Table 154: Influenza Therapeutics Market, Japan, Average Cost of Treatment, 20022009 233
Table 155: Influenza Therapeutics Market, Japan, Average Cost of Treatment, 20092016 233
Table 156: Influenza Therapeutics Market, Japan, Diseased Population(Million), 20022009 234
Table 157: Influenza Therapeutics Market, Japan, Diseased Population(Million), 20022009 234
Table 158: Influenza Therapeutics Market, Japan, Treatment Seeking Population(Million), 20022009 235
Table 159: Influenza Therapeutics Market, Japan, Treatment Seeking Population(Million), 20022009 235
Table 160: Influenza Therapeutics Market, Japan, Diagnosis Population(Million), 20022009 236
Table 161: Influenza Therapeutics Market, Japan, Diagnosis Population(Million), 20092016 236
Table 162: Influenza Therapeutics Market, Japan, Usage Patterns(Million), 20022009 238
Table 163: Influenza Therapeutics Market, Japan, Usage Patterns(Million), 20092016 239
Table 164: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase I, 2009-2010 240
Table 165: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase II, 2009-2010 242
Table 166: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase III, 2009-2010 245
Table 167: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008 249
Table 168: BioAlliance Pharma Herpes Pipeline Portfolio, February 2010 268
Table 169: Nutra Pharma Corporation Herpes Pipeline Portfolio, 2010 269
Table 170: AiCuris GmbH & Co. KG Herpes Simplex Pipeline Portfolio, 2010 270
Table 171: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical
Stage, 2008 275
Table 172: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008 276
Table 173: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III,
2008 276
Table 174: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008 277

List of Chart


Figure 1: HIV Therapeutics Market, Global, Market Overview, 2009 19
Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2016 20
Figure 3: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2000-2016 21
Figure 4: HIV Therapeutics Market, Global, Diseased Population, 20002016 23
Figure 5: HIV Therapeutics Market, Global, Treatment Seeking Population, 20002016 25
Figure 6: HIV Therapeutics Market, Global, Diagnosis Population, 20002016 27
Figure 7: HIV Therapeutics Market, Global, Prescription Population, 20002016 29
Figure 8: HIV Therapeutics Market, Global, Usage Patterns, 20002016 31
Figure 9: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m),
20002016 33
Figure 10: HIV Therapeutics Market, US, Revenue ($m), 20002016 39
Figure 11: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 20002016 41
Figure 12: HIV Therapeutics Market, US, Diseased Population,20002016 42
Figure 13: HIV Therapeutics Market, US, Treatment Seeking Population, 20002016 44
Figure 14: HIV Therapeutics Market, US, Diagnosis Population, 20002016 45
Figure 15: HIV Therapeutics Market, US, Prescription Population, 20002016 47
Figure 16: HIV Therapeutics Market, US, Usage Patterns, 20002016 49
Figure 17: HIV Therapeutics Market, Europe, Revenue ($m), 20002016 52
Figure 18: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 20002016 53
Figure 19: HIV Therapeutics Market, Europe, Diseased Population, 20002016 55
Figure 20: HIV Therapeutics Market, Europe, Treatment Seeking Population, 20002016 56
Figure 21: HIV Therapeutics Market, Europe, Diagnosis Population, 20002016 58
Figure 22: HIV Therapeutics Market, Europe, Prescription Population, 20002016 60
Figure 23: HIV Therapeutics Market, Europe, Usage Patterns, 20002016 61
Figure 24: HIV Therapeutics Market, Japan, Revenue ($m), 20002016 63
Figure 25: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 20002016 65
Figure 26: HIV Therapeutics Market, Japan, Diseased Population, 20002016 66
Figure 27: HIV Therapeutics Market, Japan, Treatment Seeking Population, 20002016 67
Figure 28: HIV Therapeutics Market, Japan, Diagnosis Population, 20002016 68
Figure 29: HIV Therapeutics Market, Japan, Prescription Population, 20002016 69
Figure 30: HIV Therapeutics Market, Japan, Usage Patterns, 20002016 70
Figure 31: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2009 75
Figure 32: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20012016 106
Figure 33: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20012016 107
Figure 34: Hepatitis Therapeutics Market, Global, Therapeutic Usage Patterns, 20012016 108
Figure 35: Hepatitis Therapeutics Market, Global, Diseases Population, 20012016 110
Figure 36: Hepatitis Therapeutics Market, Global, Treatment Seeking Population, 20012016 111
Figure 37: Hepatitis Therapeutics Market, Global, Diagnosed Population, 20012016 112
Figure 38: Hepatitis Therapeutics Market, Global, Prescription Population, 20012016 113
Figure 39: Hepatitis B and Hepatitis C Therapeutic Market, Global, Branded and Generic Drugs (%), 2009 116
Figure 40: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20012016 118
Figure 41: Hepatitis Therapeutics Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 119
Figure 42: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20012016 120
Figure 43: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($),
20012016 121
Figure 44: Hepatitis Market, Global, Hepatitis B Treatment Usage Patterns, 20012016 122
Figure 45: Hepatitis Market, Global, Hepatitis B Diseased Population, 20012016 123
Figure 46: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Seeking Population,
20012016 124
Figure 47: Hepatitis Market, Global, Hepatitis B Diagnosis Population, 20012016 125
Figure 48: Hepatitis Therapeutics Market, Global, Hepatitis B Prescription Population, 20012016 126
Figure 49: Hepatitis Therapeutics Market, Global, Hepatitis B Market Segmentation by Geography (%), 2009 and 2016 127
Figure 50: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20012016 128
Figure 51: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20012016 130
Figure 52: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($),
20012016 131
Figure 53: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns,
20012016 132
Figure 54: Hepatitis Therapeutics Market, Global, Hepatitis C Diseased Population, 20012016 134
Figure 55: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Seeking Population, 20012016 135
Figure 56: Hepatitis Therapeutics Market, Global, Hepatitis C Diagnosis Population, 20012016 136
Figure 57: Hepatitis Therapeutics Market, Global, Hepatitis C Prescription Population, 20012016 137
Figure 58: Hepatitis Therapeutics Market, Global, Hepatitis C Market Segmentation by Geography (%), 2009 and 2016 138
Figure 59: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation ($m), 20012016 139
Figure 60: Hepatitis Therapeutics Market, Global, Market Share by Geography (%), 2009 and 2016 141
Figure 61: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20012016 142
Figure 62: Hepatitis Therapeutics Market, US, Sales Value ($m), 20012016 144
Figure 63: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20012016 145
Figure 64: Hepatitis Therapeutics Market, US, Treatment Usage Patterns, 20012016 146
Figure 65: Hepatitis Therapeutics Market, US, Diseased Population, 20012016 148
Figure 66: Hepatitis Therapeutics Market, US, Treatment Seeking Population, 20012016 149
Figure 67: Hepatitis Therapeutics Market, US, Diagnosed Population, 20012016 150
Figure 68: Hepatitis Therapeutics Market, US, Prescription Population, 20012016 151
Figure 69: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m),
20012016 152
Figure 70: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20012016 154
Figure 71: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 20012016 155
Figure 72: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population, 20012016 156
Figure 73: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 20012016 157
Figure 74: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 20012016 158
Figure 75: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population, 20012016 159
Figure 76: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20012016 160
Figure 77: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012016 161
Figure 78: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 20012016 162
Figure 79: Hepatitis Therapeutics Market, Japan, Diseased Population, 20012016 164
Figure 80: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population, 20012016 165
Figure 81: Hepatitis Therapeutics Market, Japan, Diagnosed Population, 20012016 166
Figure 82: Hepatitis Therapeutics Market, Japan, Prescription Population, 20012016 167
Figure 83: Hepatitis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 169
Figure 84: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 170
Figure 85: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis B Market (%), 2010 171
Figure 86: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis C (%), 2010 176
Figure 87: Herpes Simplex Therapeutics Market, Global, Revenues ($bn), 2001-2009 192
Figure 88: Herpes Simplex Therapeutics Market, Global, Market Forecast ($bn), 2009-2016 193
Figure 89: Strategic Competitor Assessment of the Major Marketed Products in Herpes Simplex Market, 2010 195
Figure 90: Herpes Simplex Clinical Pipeline by Mechanism of Action, 2010 203
Figure 91: Influenza Therapeutics Market, Global, Market Overview, 2009-2016 208
Figure 92: Influenza Therapeutics Market, Global, Revenue ($bn), 2001-2016 209
Figure 93: Influenza Therapeutics Market, Annual Cost of Therapy, Global ($), 2002-2016 210
Figure 94: Influenza Therapeutics Market, Global Diseased Population, 2002-2016 211
Figure 95: Influenza Therapeutics Market, Global, Treatment Seeking Population, 20022016 212
Figure 96: Influenza Therapeutics Market, Global, Diagnosis Population, 20022016 213
Figure 97: Influenza Therapeutics Market, Global, Usage Patterns, 20022016 214
Figure 98: Influenza Therapeutics Market, Global, Geographical Distribution of Revenues (%),
20012016 215
Figure 99: Influenza Therapeutics Market, US, Revenue ($m), 20002016 216
Figure 100: Influenza Therapeutics Market, US, Annual Cost of Therapy ($), 20002016 217
Figure 101: Influenza Therapeutics, US, Diseased Population, 2002-2016 218
Figure 102: Influenza Therapeutics Market, US, Treatment Seeking Population, 20022016 219
Figure 103: Influenza Therapeutics Market, US, Diagnosis Population, 20022016 220
Figure 104: Influenza Therapeutics Market, The US, Prescription Share of Major Drugs(%),
2001-2016 221
Figure 105: Influenza Therapeutics Market, US, Usage Patterns, 20012016 222
Figure 106: Influenza Therapeutics Market, Europe, Revenue ($bn), 20012016 224
Figure 107: Influenza Therapeutics Market, Europe, Average Cost of Treatment ($), 20002016 225
Figure 108: Influenza Therapeutics Market, Europe, Diseased Population, 20022016 226
Figure 109: Influenza Therapeutics Market, Europe, Treatment Seeking Population, 20002016 227
Figure 110: Influenza Therapeutics Market, Europe, Diagnosis Population, 20012016 228
Figure 111: Influenza Therapeutics Market, Europe, Prescription Population, 20012016 229
Figure 112: Influenza Therapeutics Market, Europe, Usage Patterns, 20012016 230
Figure 113: Influenza Therapeutics Market, Japan, Revenue ($bn), 20012016 232
Figure 114: Influenza Therapeutics Market, Japan, Average Cost of Treatment ($), 20012016 233
Figure 115: Influenza Therapeutics Market, Japan, Diseased Population, 20022016 234
Figure 116: Influenza Therapeutics Market, Japan, Treatment Seeking Population, 20002016 235
Figure 117: Influenza Therapeutics Market, Japan, Diagnosis Population, 20012016 236
Figure 118: Influenza Therapeutics Market, Japan, Prescription Population, 20012016 237
Figure 119: Influenza Therapeutics Market, Europe, Usage Patterns, 20012016 238
Figure 120: Influenza Therapeutics Market, Global, Deals by Geography and Type, 2009-2010 240
Figure 121: HIV Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with
Respect to Revenues, 2006-2008 247
Figure 122: HIV Therapeutics Market, Global, Competitive Analysis of Top 4 Manufacturers,
20062009 248
Figure 123: HIV Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2009 250
Figure 124: HIV Therapeutics Market, GSK, HIV Revenue as Percentage of Total Revenue, 2009 251
Figure 125:HIV Therapeutics Market, BMS, HIV Revenue as Percentage of Total Revenue, 2009 253
Figure 126:HIV Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2009 254
Figure 127:HIV Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2009 256
Figure 128:Hepatitis B and Hepatitis C Therapeutics Markets, Global, Market Share of Top
Manufacturers (%), 2010 258
Figure 129:Hepatitis Vaccine Market, Global, Revenue of Top Players (%), 2010 259
Figure 130:Merck & Co., Inc., SWOT Analysis, 2010 260
Figure 131:F. Hoffmann-La Roche Ltd., SWOT Analysis, 2010 263
Figure 132:GlaxoSmithKline plc, SWOT Analysis, 2010 265
Figure 133:Herpes Simplex, Global, Companies That Have the Highest Number of Molecules in
the Pipeline, 2010 267
Figure 134:HIV Therapeutics Market, Global, Deals by Geography and Type, 2009-10 271
Figure 135:HIV Therapeutics Market, Global, M&A Deals, 2008 272
Figure 136:HIV Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-2009 274
Figure 137:Hepatitis Therapeutics Market, Global, M&A Deals by Geography, (%), 2010 278
Figure 138:Hepatitis Therapeutics Health Market, Global, M&A Deals by Type, (%), 2010 279
Figure 139:Hepatitis Therapeutics Market, Global, Major Licensing Agreements By Indication (%),
2010 280
Figure 140:GBI Research Market Forecasting Model 295

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *